1. Home
  2. BTX vs GYRE Comparison

BTX vs GYRE Comparison

Compare BTX & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTX
  • GYRE
  • Stock Information
  • Founded
  • BTX N/A
  • GYRE 2002
  • Country
  • BTX United States
  • GYRE United States
  • Employees
  • BTX N/A
  • GYRE N/A
  • Industry
  • BTX
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • BTX
  • GYRE Health Care
  • Exchange
  • BTX Nasdaq
  • GYRE Nasdaq
  • Market Cap
  • BTX 854.3M
  • GYRE 897.1M
  • IPO Year
  • BTX N/A
  • GYRE N/A
  • Fundamental
  • Price
  • BTX $7.32
  • GYRE $6.65
  • Analyst Decision
  • BTX
  • GYRE
  • Analyst Count
  • BTX 0
  • GYRE 0
  • Target Price
  • BTX N/A
  • GYRE N/A
  • AVG Volume (30 Days)
  • BTX 581.4K
  • GYRE 80.4K
  • Earning Date
  • BTX 08-15-2025
  • GYRE 08-12-2025
  • Dividend Yield
  • BTX 13.96%
  • GYRE N/A
  • EPS Growth
  • BTX N/A
  • GYRE N/A
  • EPS
  • BTX N/A
  • GYRE 0.02
  • Revenue
  • BTX N/A
  • GYRE $100,643,000.00
  • Revenue This Year
  • BTX N/A
  • GYRE $21.04
  • Revenue Next Year
  • BTX N/A
  • GYRE $89.64
  • P/E Ratio
  • BTX N/A
  • GYRE $82.27
  • Revenue Growth
  • BTX N/A
  • GYRE N/A
  • 52 Week Low
  • BTX $5.10
  • GYRE $6.11
  • 52 Week High
  • BTX $8.31
  • GYRE $19.00
  • Technical
  • Relative Strength Index (RSI)
  • BTX N/A
  • GYRE 36.82
  • Support Level
  • BTX N/A
  • GYRE $7.09
  • Resistance Level
  • BTX N/A
  • GYRE $7.89
  • Average True Range (ATR)
  • BTX 0.00
  • GYRE 0.38
  • MACD
  • BTX 0.00
  • GYRE -0.02
  • Stochastic Oscillator
  • BTX 0.00
  • GYRE 5.08

About BTX BlackRock Technology and Private Equity Term Trust Common Shares of Beneficial Interest

BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: